Targeted Genetics signs subcontract with Children's Hospital of Philadelphia for AIDS vaccine candidate

By Ted A. Knutson

Washington, March 8 - Targeted Genetics Corp. said Wednesday it entered into a collaboration agreement on Feb. 10 with the Children's Hospital of Philadelphia, or CHOP, relating to the development of an AIDS vaccine candidate.

The agreement was entered into pursuant to a contract awarded to Columbus Children's Research Institute in collaboration with CHOP by National Institute of Allergy and Infectious Disease.

On Nov. 30, the National Institute of Allergy and Infectious Disease awarded a $21.75 million contract to Columbus Children's Research Institute to expand adeno-associated viral vector-based HIV vaccine development, of which Targeted Genetics as a subcontractor is eligible to receive up to $18 million over five years.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

Targeted Genetics is a Seattle-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.